Rabbie K. Hanna, MD, specializes in
Gynecologic Oncology. Dr. Hanna is certified by the American Board of Obstetrics and Gynecology in both Obstetrics and Gynecology and Gynecologic Oncology. He has special expertise in
Robotic-assisted Surgery.
Licensed to practice in Michigan, Dr. Hanna is a Member of the Society of Gynecologic Oncology, American Society of Clinical Oncology (ASCO) and the American College of Obstetrics and Gynecology (ACOG), among others. He is currently a Clinical Assistant Professor in Obstetrics and Gynecology at Wayne State University, Detroit, MI.
Dr. Hanna is an attending physician of Gynecologic Oncology at the Henry Ford Health System in Detroit, Michigan, in addition to Genesys Health System in Grand Blanc, MI and Hurley Medical Center in Flint, MI.
Areas of Specialization:
- Gynecologic Cancer
- Minimally Invasive Surgery
- Robotic Surgery
- Gynecologic Surgery
- Endometrial Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
| Cervical CancerVulvar CancerVaginal CancerLaparoscopically Assisted Vaginal HysterectomyRobotic HysterectomyEndometrial BiopsyLeiomyomaOvarian Cancer |
Author - Dr. Hanna has published numerous book chapters, peer-reviewed articles, and abstracts on topics within his expertise.
Speaker - Dr. Hanna has delivered Gynecologic Oncology seminars and presentations around the nation to such entities as the Society of Gynecologic Oncology and others.
Honors and Awards - Throughout the years, Dr. Hanna has been recognized for his outstanding achievement and ability. Among many include the 2015 nomination for membership into the Gold Humanism Honor Society. In 2012, he was honored with the “Outstanding Teaching Award” presented by the Henry Ford Hospital/Wayne State University Obstetrics and Gynecology Residents and other teaching awards.
The primary management of hydatidiform moles remains surgical evacuation followed by human chorionic gonadotropin level monitoring. Although suction dilatation and evacuation is the most frequent technique for molar evacuation, hysterectomy is a viable option in older patients who do not wish to preserve fertility. Despite advances in chemotherapy regimens for treating malignant gestational trophoblastic neoplasia, hysterectomy and other extirpative procedures continue to play a role in the management of patients with both lowrisk and high-risk gestational trophoblastic neoplasia.
Abstract Aim: To evaluate clinical outcomes and identify factors predictive for recurrence in patients with 1988 (FIGO) stage IA uterine endometrioid carcinoma. Patients and Methods: Patients who underwent hysterectomy for stage IA carcinoma were identified in our database. Fisher's exact and ?2 tests were used to identify factors that influenced outcome. Survival plots were generated according to Kaplan-Meier product-limit method and the log-rank test was used to determine significance. Results: A total of 121 patients were identified.
Purpose Uterine clear-cell carcinoma (UCCC) is a rare subset of type II endometrial carcinoma with a poor prognosis relative to the most common type of endometrioid carcinoma. Due to its rarity, there has been limited direct evidence of the efficacy of specific adjuvant therapy posthysterectomy in women with UCCC. We present a review of current literature regarding adjuvant therapy of uterine clear cell carcinoma.
OBJECTIVE: To report on the perioperative outcomes after robotically assisted total hysterectomy for benign indications in a large patient population with predominantly complex pathology.
